

Subject index¹

Volume 65, issues 1 and 2 (2005)

Acyclovir; Vidarabine; Varicella-zoster virus; Infection; Drug resistance **65**, 49

AIDS; HIV; Reverse transcriptase; Ribonuclease H; Antiviral agents; Diketoacid **65**, 117

Antiviral agent; SARS-CoV; siRNA; Spike protein **65**, 45

Antiviral agents; HIV; AIDS; Reverse transcriptase; Ribonuclease H; Diketoacid **65**, 117

Antiviral screen; HIV; Reporter virus; Cell-based assay **65**, 107

Antiviral therapy; Guinea pig; Cytomegalovirus; CMV infection; Immunocompromised animal model; Real-time PCR; BAY 38-4766; Placenta **65**, 35

Antiviral; Herpesvirus; 4-Oxo-dihydroquinolines; Non-nucleosides; Polymerase **65**, 97

Arava; Leflunomide; A771726; DHODH; EGF receptor **65**, 1

BAY 38-4766; Guinea pig; Cytomegalovirus; Antiviral therapy; CMV infection; Immunocompromised animal model; Real-time PCR; Placenta **65**, 35

Cell-based assay; HIV; Antiviral screen; Reporter virus **65**, 107

CMV infection; Guinea pig; Cytomegalovirus; Antiviral therapy; Immunocompromised animal model; Real-time PCR; BAY 38-4766; Placenta **65**, 35

Combination antiviral therapy; Hepatitis C Virus; Interferon; Cytokines; HCV replicon **65**, 23

Coronavirus; Severe acute respiratory syndrome (SARS); Viral proteins **65**, 69

CpG-DNA; Orthopoxvirus; Innate immunity **65**, 87

Cytokines; Hepatitis C Virus; Combination antiviral therapy; Interferon; HCV replicon **65**, 23

Cytomegalovirus; Guinea pig; Antiviral therapy; CMV infection; Immunocompromised animal model; Real-time PCR; BAY 38-4766; Placenta **65**, 35

DHODH; Arava; Leflunomide; A771726; EGF receptor **65**, 1

Diketoacid; HIV; AIDS; Reverse transcriptase; Ribonuclease H; Antiviral agents **65**, 117

Drug resistance; Vidarabine; Acyclovir; Varicella-zoster virus; Infection **65**, 49

EGF receptor; Arava; Leflunomide; A771726; DHODH **65**, 1

Fetus; West Nile virus; Pregnancy; Placenta; Immunoglobulin therapy; Flavivirus **65**, 79

Flavivirus; West Nile virus; Pregnancy; Fetus; Placenta; Immunoglobulin therapy **65**, 79

Guinea pig; Cytomegalovirus; Antiviral therapy; CMV infection; Immunocompromised animal model; Real-time PCR; BAY 38-4766; Placenta **65**, 35

HCV replicon; Hepatitis C Virus; Combination antiviral therapy; Interferon; Cytokines **65**, 23

Hepatitis C Virus; Combination antiviral therapy; Interferon; Cytokines; HCV replicon **65**, 23

Herpesvirus; Antiviral; 4-Oxo-dihydroquinolines; Non-nucleosides; Polymerase **65**, 97

HIV; AIDS; Reverse transcriptase; Ribonuclease H; Antiviral agents; Diketoacid **65**, 117

HIV; Antiviral screen; Reporter virus; Cell-based assay **65**, 107

HIV; Microbicides; Reverse transcriptase inhibitor **65**, 57

Immunocompromised animal model; Guinea pig; Cytomegalovirus; Antiviral therapy; CMV infection; Real-time PCR; BAY 38-4766; Placenta **65**, 35

Immunoglobulin therapy; West Nile virus; Pregnancy; Fetus; Placenta; Flavivirus **65**, 79

Infection; Vidarabine; Acyclovir; Varicella-zoster virus; Drug resistance **65**, 49

Innate immunity; CpG-DNA; Orthopoxvirus **65**, 87

Interferon; Hepatitis C Virus; Combination antiviral therapy; Cytokines; HCV replicon **65**, 23

L protein; Respiratory syncytial virus; YM-53403; Ribavirin **65**, 125

¹The above Subject index includes issues 65/1 and 65/2. There is no Subject index for 65(3).

Leflunomide; Arava; A771726; DHODH; EGF receptor **65**, 1

Lymphocyte activation; Reverse transcriptase; Lymphoproliferative disease **65**, 13

Lymphoproliferative disease; Lymphocyte activation; Reverse transcriptase **65**, 13

Microbicides; HIV; Reverse transcriptase inhibitor **65**, 57

Non-nucleosides; Herpesvirus; Antiviral; 4-Oxo-dihydroquinolines; Polymerase **65**, 97

Orthopoxvirus; CpG-DNA; Innate immunity **65**, 87

4-Oxo-dihydroquinolines; Herpesvirus; Antiviral; Non-nucleosides; Polymerase **65**, 97

Placenta; Guinea pig; Cytomegalovirus; Antiviral therapy; CMV infection; Immunocompromised animal model; Real-time PCR; BAY 38-4766 **65**, 35

Placenta; West Nile virus; Pregnancy; Fetus; Immunoglobulin therapy; Flavivirus **65**, 79

Polymerase; Herpesvirus; Antiviral; 4-Oxo-dihydroquinolines; Non-nucleosides **65**, 97

Pregnancy; West Nile virus; Fetus; Placenta; Immunoglobulin therapy; Flavivirus **65**, 79

Real-time PCR; Guinea pig; Cytomegalovirus; Antiviral therapy; CMV infection; Immunocompromised animal model; BAY 38-4766; Placenta **65**, 35

Reporter virus; HIV; Antiviral screen; Cell-based assay **65**, 107

Respiratory syncytial virus; YM-53403; Ribavirin; L protein **65**, 125

Reverse transcriptase inhibitor; HIV; Microbicides **65**, 57

Reverse transcriptase; HIV; AIDS; Ribonuclease H; Antiviral agents; Diketoacid **65**, 117

Reverse transcriptase; Lymphocyte activation; Lymphoproliferative disease **65**, 13

Ribavirin; Respiratory syncytial virus; YM-53403; L protein **65**, 125

Ribonuclease H; HIV; AIDS; Reverse transcriptase; Antiviral agents; Diketoacid **65**, 117

SARS-CoV; siRNA; Spike protein; Antiviral agent **65**, 45

Severe acute respiratory syndrome (SARS); Coronavirus; Viral proteins **65**, 69

siRNA; SARS-CoV; Spike protein; Antiviral agent **65**, 45

Spike protein; SARS-CoV; siRNA; Antiviral agent **65**, 45

Varicella-zoster virus; Vidarabine; Acyclovir; Infection; Drug resistance **65**, 49

Vidarabine; Acyclovir; Varicella-zoster virus; Infection; Drug resistance **65**, 49

Viral proteins; Severe acute respiratory syndrome (SARS); Coronavirus **65**, 69

West Nile virus; Pregnancy; Fetus; Placenta; Immunoglobulin therapy; Flavivirus **65**, 79

YM-53403; Respiratory syncytial virus; Ribavirin; L protein **65**, 125